Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
株式のランク #33956
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
株価
$17.15
最終同期: 2026-08-03
時価総額
$6.51M
変化(1日)
9.80%
変化(1年)
289.77%
US
取引 Galera Therapeutics, Inc. (GRTX)

カテゴリー

Galera Therapeutics, Inc.(GRTX)のP/S比率
August 2026 時点のP/S比率 TTM: 0.00
Galera Therapeutics, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0.00 です。2023 年末時点でのP/S比率は 0.00 でした。
Galera Therapeutics, Inc. の P/S 比率の履歴(2017 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
同業他社のP/S比率